Pacylex Pharmaceuticals to Present Cancer Treatment Advances at Major February Conferences

Pacylex Pharmaceuticals will present significant advances in their cancer treatment portfolio at three major industry conferences this February, highlighting their development of N-myristoyltransferase inhibitors for both hematologic cancers and solid tumor treatments. The company's presentations will focus on zelenirstat, their oral medication for hematologic cancers, and their development of NMTis as payloads for antibody drug conjugates in solid tumor treatments. Michael Kamdar, a board member, will present at the Precision Medicine World Conference (PMWC) 2025 in Silicon Valley on February 6, while CEO Michael Weickert will represent the company at both the OBIO® Investment Summit and Early Technology Showcase in Toronto and the BIO CEO and Investors conference in New York.

These presentations come at a pivotal time as Pacylex initiates a new study of oral zelenirstat in Acute Myeloid Leukemia, for which they have already secured both Orphan and Fast Track Designations from the FDA. The company's lead drug, zelenirstat, has demonstrated promising results in initial studies, with a recently completed Phase 1 multiple ascending dose study showing acceptable safety and tolerability profiles. Pharmacokinetics support once-daily oral dosing, and the drug has shown the ability to kill cancer cells in vitro while demonstrating regression of hematologic malignancies and growth inhibition in lung and breast cancer tumors in animal models.

Pacylex's portfolio includes 503 small molecule NMTis, with 28 high-potency compounds representing a significant advancement in cancer treatment. The NMTi technology works through multiple mechanisms to disrupt cancer cell survival pathways, showing particular promise in addressing drug-resistant cancers. The compounds have demonstrated limited acquired resistance despite long-term exposure, suggesting potential durability in treatment outcomes. The development of NMTis as ADC payloads marks a significant innovation in cancer treatment, as these inhibitors work by interfering with multiple essential cancer cell pathways including receptor tyrosine kinases, Wnt pathway, and PI3K/AKT/mTOR signaling.

This multi-targeted approach could potentially provide more effective treatment options for patients with solid tumors who have limited alternatives. With support from organizations including the US Department of Defense, The Cure Cancer Foundation, Alberta Cancer Foundation, and Alberta Innovates, Pacylex continues to advance its clinical studies. The company's technology represents an important step forward in addressing the challenges of drug resistance in cancer treatment, potentially offering new hope for patients with various forms of cancer who have exhausted conventional treatment options.